Suppr超能文献

非肌层浸润性膀胱癌患者膀胱内卡介苗单月灌注维持治疗与西南肿瘤协作组方案的比较——单机构回顾性分析

Comparison of Single Monthly Instillations of Intra-Vesical Bacillus Calmette-Guerin Maintenance Therapy with Southwest Oncology Group Regimen in Non-Muscle Invasive Bladder Cancer Patients-A Retrospective Analysis In a Single Institute.

作者信息

Lashay Alireza, Taleghani Saeed, Masoumi Navid

机构信息

Department of urology, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran/Iran.

Urology Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran/Iran.

出版信息

Urol J. 2021 May 8;19(2):106-110. doi: 10.22037/uj.v18i.6491.

Abstract

PURPOSE

To compare the efficacy and complication rate of monthly instillations of Bacillus Calmette-Guerin (BCG) as maintenance therapy in intermediate and high risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with the current standard Southwest Oncology Group (SWOG) protocol.

MATERIALS AND METHODS

In this observational retrospective study, 40 intermediate and high risk NMIBC patients, receiving standard BCG maintenance regimen, were compared with another 40 NMIBC patients, undergoing monthly intra-vesical instillations of BCG with regard to recurrence, progression and major and minor adverse effects.

RESULTS

The two groups were similar in their basic characteristics except for the older age in the monthly instillation group ( 70.95 ± 9.66 years vs. 64 ± 8.8, p = 0.001). Study objectives between the monthly instillation group and the standard group, including recurrence ( 17.5 % vs. 25%, p = 0.34) and progression rate ( 7.5% vs. 10%, p = 0.54) did not show statistically significant difference. Major and minor complication rate also did not show any difference between the two groups.

CONCLUSION

In addition to the currently recommended standard protocol of BCG maintenance therapy, our study shows that the monthly regimen can be recommended in intermediate and high risk NMIBC patients without compromising the efficacy of the treatment.

摘要

目的

比较每月膀胱灌注卡介苗(BCG)作为维持治疗在中高危非肌层浸润性膀胱癌(NMIBC)患者中的疗效和并发症发生率与当前标准的西南肿瘤协作组(SWOG)方案。

材料与方法

在这项观察性回顾性研究中,将40例接受标准BCG维持方案的中高危NMIBC患者与另外40例每月接受膀胱内BCG灌注的NMIBC患者在复发、进展以及主要和次要不良反应方面进行比较。

结果

两组患者的基本特征相似,但每月灌注组患者年龄较大(70.95±9.66岁 vs. 64±8.8岁,p = 0.001)。每月灌注组与标准组之间的研究目标,包括复发率(17.5% vs. 25%,p = 0.34)和进展率(7.5% vs. 10%,p = 0.54),均未显示出统计学上的显著差异。两组之间的主要和次要并发症发生率也没有差异。

结论

除了目前推荐的BCG维持治疗标准方案外,我们的研究表明,在不影响治疗效果的情况下,每月方案可推荐用于中高危NMIBC患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验